Cargando…

Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma

There are unmet medical needs for patients with lung squamous cell carcinoma (LSCC). Therefore, in this study, we explored the antitumor potential of third-generation glypican 3 (GPC3)-redirected chimeric antigen receptor (CAR)-engineered T lymphocytes (CARgpc3 T cells) in tumor models of LSCC. Firs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Kesang, Pan, Xiaorong, Bi, Yanyu, Xu, Wen, Chen, Cheng, Gao, Huiping, Shi, Bizhi, Jiang, Hua, Yang, Shengli, Jiang, Liyan, Li, Zonghai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823050/ https://www.ncbi.nlm.nih.gov/pubmed/26684028 http://dx.doi.org/10.18632/oncotarget.6595

Ejemplares similares

Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII(+)PTEN(−) glioblastoma in vivo
por: Xu, Wen, et al.
Publicado: (2016)

Synergistic antitumor efficacy against the EGFRvIII(+)HER2(+) breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12
por: Xu, Wen, et al.
Publicado: (2015)

Development of anti-GPC-1 (glypican-1)-CAR-T cells for adoptive T cell immunotherapies for squamous cell carcinoma
por: Yaguchi, Tomonori, et al.
Publicado: (2015)

Cancer immunotherapy‐targeted glypican‐3 or neoantigens
por: Shimizu, Yasuhiro, et al.
Publicado: (2018)

Redirecting T cells to glypican-3 with 28.41BB.ζ and 28.ζ-41BBL CARs for hepatocellular carcinoma treatment
por: Ma, Haili, et al.
Publicado: (2017)

A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells
por: Lund, Maria E., et al.
Publicado: (2020)

Next-Generation Cancer Immunotherapy Targeting Glypican-3
por: Shimizu, Yasuhiro, et al.
Publicado: (2019)

Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial
por: Komatsu, Shun-ichiro, et al.
Publicado: (2022)

Redirecting the focus of cancer immunotherapy to premalignant conditions
por: Young, M. Rita I.
Publicado: (2017)

Glypicans
por: Filmus, Jorge, et al.
Publicado: (2008)

Novel Redirected T–Cell Immunotherapies for Advanced Prostate Cancer
por: Dorff, Tanya B., et al.
Publicado: (2022)

Glypican-3 Expression in Patients with Oral Squamous Cell Carcinoma
por: Andisheh-Tadbir, Azadeh, et al.
Publicado: (2020)

An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment
por: Wang, Yi, et al.
Publicado: (2019)

Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager
por: Bi, Yanyu, et al.
Publicado: (2017)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

Combined Adjuvant of Poly I:C Improves Antitumor Effects of CAR-T Cells
por: Di, Shengmeng, et al.
Publicado: (2019)

Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy
por: He, Jia, et al.
Publicado: (2012)

Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level
por: Song, De-Gang, et al.
Publicado: (2016)

EGFRvIII Mediates Hepatocellular Carcinoma Cell Invasion by Promoting S100 Calcium Binding Protein A11 Expression
por: Luo, Xiaoying, et al.
Publicado: (2013)

Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
por: Mensali, Nadia, et al.
Publicado: (2019)

Redirecting host preexisting influenza A virus immunity for cancer immunotherapy
por: Chaganty, Bharat K. R., et al.
Publicado: (2021)

Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell–Redirected Bispecific Antibodies
por: Lussana, Federico, et al.
Publicado: (2021)

EGFR modulates monounsaturated fatty acid synthesis through phosphorylation of SCD1 in lung cancer
por: Zhang, Jiqin, et al.
Publicado: (2017)

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytes
por: Caruana, Ignazio, et al.
Publicado: (2015)

Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells
por: Jiang, Hua, et al.
Publicado: (2017)

Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells
por: Sommaggio, Roberta, et al.
Publicado: (2020)

CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma
por: Giraudo, Lidia, et al.
Publicado: (2023)

P64. T cell re-direction against Glypican-3 for immunotherapy of hepatocellular carcinoma
por: Dargel, C, et al.
Publicado: (2014)

Chimeric anti-GPC3 sFv-CD3ε receptor-modified T cells with IL7 co-expression for the treatment of solid tumors
por: Sun, Yansha, et al.
Publicado: (2022)

Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
por: Mensali, Nadia, et al.
Publicado: (2019)

Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies
por: Abbott, Rebecca C., et al.
Publicado: (2020)

Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma
por: Hara, Hisashi, et al.
Publicado: (2016)

Suicide Gene Therapy to Increase the Safety of Chimeric Antigen Receptor-Redirected T Lymphocytes
por: Casucci, Monica, et al.
Publicado: (2011)

A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma
por: Munekage, Eri, et al.
Publicado: (2021)

Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report
por: Sun, Hongwei, et al.
Publicado: (2022)

CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy
por: Rotolo, Ramona, et al.
Publicado: (2019)

FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer
por: Liu, Yifan, et al.
Publicado: (2023)

A Small Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts
por: Tóth, Gábor, et al.
Publicado: (2020)

Quantitative study of cytotoxic T-lymphocyte immunotherapy for nasopharyngeal carcinoma
por: Shengjun, Wang, et al.
Publicado: (2012)

Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies
por: Zhao, Dong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_873tfbks80i2cpmkjink6r2s1r